

# Polypharmacy: Use of Multiple CNS-Active Medications in Older Adults (POLY-CNS)

## APPLICABLE LINES OF BUSINESS

- Medicare

## MEASURE DESCRIPTION

The percentage of individuals  $\geq 65$  years of age with concurrent use of  $\geq 3$  unique central-nervous system (CNS)-active medications.<sup>1</sup> A lower rate indicates better performance.

## APPLICABLE MEDICATIONS

Antiepileptic Medications		
• brivaracetam	• lacosamide	• primidone
• cannabidiol	• lamotrigine	• rufinamide
• carbamazepine	• levetiracetam	• stiripentol
• divalproex sodium	• methsuximide	• tiagabine
• eslicarbazepine	• oxcarbazepine	• topiramate
• ethosuximide	• perampanel	• valproic acid
• ethotoin	• phenobarbital	• vigabatrin
• felbamate	• phenytoin	• zonisamide
• gabapentin	• pregabalin	
Antipsychotic Medications		
• aripiprazole	• iloperidone	• pimavanserin
• asenapine	• loxapine	• pimozide
• brexpiprazole	• lumateperone	• quetiapine
• cariprazine	• lurasidone	• risperidone
• chlorpromazine	• molindone	• thioridazine
• clozapine	• olanzapine	• thiothixene
• fluphenazine	• paliperidone	• trifluoperazine
• haloperidol	• perphenazine	• ziprasidone

## Benzodiazepines & Nonbenzodiazepine Sedative/Hypnotic Medications

- |                    |               |             |
|--------------------|---------------|-------------|
| • alprazolam       | • estazolam   | • quazepam  |
| • chlordiazepoxide | • eszopiclone | • temazepam |
| • clobazam         | • flurazepam  | • triazolam |
| • clonazepam       | • lorazepam   | • zaleplon  |
| • clorazepate      | • midazolam   | • zolpidem  |
| • diazepam         | • oxazepam    |             |

## Opioid Medications

- |                   |                 |               |
|-------------------|-----------------|---------------|
| • benzhydrocodone | • hydrocodone   | • opium       |
| • buprenorphine   | • hydromorphone | • oxycodone   |
| • butorphanol     | • levorphanol   | • oxymorphone |
| • codeine         | • meperidine    | • tapentadol  |
| • dihydrocodeine  | • methadone     | • tramadol    |
| • fentanyl        | • morphine      |               |

## Antidepressant Medications: SNRIs, SSRIs, & TCAs

- |                  |                   |                 |
|------------------|-------------------|-----------------|
| • amitriptyline  | • duloxetine      | • nortriptyline |
| • amoxapine      | • escitalopram    | • paroxetine    |
| • citalopram     | • fluoxetine      | • protriptyline |
| • clomipramine   | • fluvoxamine     | • sertraline    |
| • desipramine    | • imipramine      | • trimipramine  |
| • desvenlafaxine | • levomilnacipram | • venlafaxine   |
| • doxepin        | • milnacipram     |                 |

## EXCLUSIONS

Patients are excluded if they:

- Received [hospice care](#) during the measurement year
- Have a seizure disorder diagnosis during the measurement year

## TIPS FOR SUCCESS

- Leverage electronic medical records (EMR) to identify prescribing that meets polypharmacy criteria. Share lists with providers in the practice for review.
- Conduct an annual review of a patient's medication list and assess appropriateness of each drug.
- Consider discontinuing medications that have no indication, are a part of a prescribing cascade, or lack of benefit.
- Use the lowest effective dose of medications to reduce the risk of adverse drug events.
- Discuss the benefits, risks, and availability of non-pharmacological therapies (e.g., chiropractic, acupuncture, and physical therapy) with your patient.
- Educate the patient on the side effects of medications, such as cognitive decline, cardiac conduction abnormalities, respiratory suppression, increased fall risk, and what to do if side effects appear.
- Reinforce the treatment plan and evaluate the medication regimen considering presence or absence of side effects, potential costs, and provide clear written instructions for medication schedule.